Sixty-nine people living with ALS in Canada, Italy and Israel received either PrimeC or placebo for six months as part of the randomized portion of the trial, which is now complete. NeuroSense announced that it expects to release safety and clinical efficacy results next month.

Investigators at the University of Michigan have developed an environmental risk score based on a mixture of pesticides found in the blood. Greater exposure to these chemicals was associated with an increased risk of developing ALS.

More News:

International Workshop Lays Foundation for Guidance on Clinical Care of People at Elevated Genetic Risk for ALS and FTD

FDA Awards Nearly $17 Million Through Rare Neurodegenerative Disease Grant Program, Including Support for ALS Research

First-in-Human Clinical Trial of Neuralink’s Brain-Computer Interface Technology Is Open for Recruitment

NeuroSense's PrimeC Shown to Affect Neuron Survival in ALS Cell Model

Muscle Strength Correlated with Functional Outcomes in Phase 2 Analysis

Genome-Wide Analyses Identify NEAT1 as Genetic Modifier of Age at Onset of ALS

Clinical trials and experimental treatments are often the first things that come to mind when thinking about ALS research. However, there are other types of research that contribute to our understanding of ALS and can be done from the comfort of your home.

ALS Focus is our patient- and caregiver-led survey program that asks people living with ALS and current and past caregivers about their needs and challenges so we can find solutions. By registering to participate in ALS Focus surveys and sharing your experiences, you can help strengthen care, accelerate therapy development, improve clinical trials, influence insurance coverage decisions and more.

Register to participate in future surveys HERE.

The ALS Association Welcomes 20th Class of Safenowitz Postdoctoral Fellows

Breaking Down Barriers for ALS: On the Quest for a Cure

Engaging the Whole World to End ALS

Subscribe today to follow our weekly blog and stay up to date with what’s happening in the ALS community. Visit our website HERE.

Clinical research is the only way that promising laboratory science can be translated into treatments and cures for ALS and other neurological diseases. People with ALS, along with family members and caregivers, are essential partners in this research. For the most accurate and up-to-date information on both federally and privately funded clinical studies focusing on ALS and other similar motor neuron diseases, visit our website.

The National ALS Registry may be the single largest ALS research project ever created and is designed to identify ALS cases from throughout the entire United States. Every person living with ALS in the U.S. can take part, and there is no fee to participate. 

The ALS Association partners with the Northeast ALS Consortium (NEALS) to provide educational webinars for people with ALS, caregivers, and the broader ALS community. Topics include updates on clinical trials, best practices for clinical care, and current research efforts in ALS causes and treatments. 

For more details about current ALS research, our programs and awards, and the projects we fund, visit als.org/research.

Stay up to date with the latest news in ALS care by signing up for our quarterly e-newsletter, Care Matters.

We welcome all feedback, comments and questions you may have on anything about the information provided, suggestions of topics you would like to see in future newsletters or thoughts to help us improve. Please email us at communication@als.org.

Research Matters will arrive in your inbox on the last Thursday of each month. To unsubscribe from future issues, please update your email preferences.